The Amino Acid Sequence in Fibrin Responsible for High Affinity Thrombin Binding^[*]

Summary

Human fibrin has a low affinity thrombin binding site in its E domain and a high affinity binding site in the carboxy-terminal region of its variant ’ chain (’408-427). Comparison of the ’ amino acid sequence (VRPEHPAETEYDSLYPEDDL) with other protein sequences known to bind to thrombin exosites such as those in GPIb , the platelet thrombin receptor, thrombomodulin, and hirudin suggests no homology or consensus sequences, but Glu and Asp enrichment are common to all. Tyrosine sulfation in these sequences enhances thrombin exosite binding, but this has not been uniformly investigated. The fibrinogen ’ chain mass determined by electrospray ionization mass spectrometry, was 50,549 Da, a value 151 Da greater than predicted from its amino acid/carbohydrate sequence. Since each sulfate group increases mass by 80 Da, this indicates that both tyrosines at 418 and 422 are sulfated. A series of overlapping ’ peptides was prepared for evaluation of their inhibition of ¹²⁵I-labeled PPACK-thrombin binding to fibrin. ’414-427 was as effective an inhibitor as ’408-427 and its binding affinity was dependent on all carboxy-terminal residues. Mono Tyr-sulfated peptides were prepared by substituting non-sulfatable Phe for Tyr at ’ 418 or 422. Sulfation at either Tyr residue increased binding competition compared with non-sulfated peptides, but was less effective than doubly sulfated peptides, which had 4 to 8-fold greater affinity. The reverse ’ peptide or the forward sequence with repositioned Tyr residues did not compete well for thrombin binding, indicating that the positions of charged residues are important for thrombin binding affinity

Keywords

Fibrin - thrombin - exosite binding - tyrosine-sulfation

^* This investigation was supported by Grant-In-Aid 97-GB-88 from the Wisconsin Affiliate of the American Heart Association and by NHLBI Grant HL59507

• References

• 1 Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. III. Identification of γ chain variants. J Biol Chem 1972; 247: 5223-7.
• 2 Mosesson MW, Finlayson JS. Subfractions of human fibrinogen: preparation and analysis. J Lab Clin Med 1963; 62: 663-74.
• 3 Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma’). Proc Natl Acad Sc USA 1980; 77: 5069-73.
• 4 Chung DW, Davie EW. γ and γ’ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984; 23: 4232-6.
• 5 Wolfenstein-Todel C, Mosesson MW. Carboxy-terminal amino acid sequence of a human fibrinogen γ chain variant (γ’). Biochemistry 1981; 20: 6146-9.
• 6 Stubbs MT, Bode W. A player of many parts: The spotlight falls on thrombin’s structure. Thromb Res 1993; 69: 1-58.
• 7 Binnie CG, Lord ST. The fibrinogen sequences that interact with thrombin. Blood 1993; 81: 3186-92.
• 8 Fenton JW II, Olson TA, Zabinski MP, Wilner GD. Anion-binding exosite of human α-thrombin and fibrin(ogen) recognition. Biochemistry 1988; 27: 7106-12.
• 9 Noé G, Hofsteenge J, Rovelli G, Stone SR. The use of sequence-specific antibodies to identify a secondary binding site in thrombin. J Biol Chem 1988; 263: 11729-35.
• 10 Meh DA, Siebenlist KR, Mosesson MW. Identification and characterization of the thrombin binding sites on fibrin. J Biol Chem 1996; 271: 23121-5.
• 11 Van Deerlin V, Tollefsen DM. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. J Biol Chem 1991; 266: 20223-31.
• 12 Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci, US A9-1-1999; 96: 11189-93.
• 13 Herbert J-M, Dupuy E, Laplace M-C, Zini J-M, Bar Shavit R, Tobelem G. Thrombin induces endothelial cell growth via both a proteolytic and a nonproteolytic pathway. Biochem J 1994; 303: 227-31.
• 14 Kanthou C, Benzakour O, Patel G, Deadman J, Kakkar VV, Lupu F. Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in vascular smooth muscle cells. Thromb Haemost 1995; 74: 1340-7.
• 15 Suzuki K, Nishioka J. A thrombin-based peptide corresponding to the sequence of the thrombomodulin-binding site blocks the procoagulant activities of thrombin. J Biol Chem 1991; 266: 18498-501.
• 16 Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 869298.
• 17 Naski MC, Fenton JW II, Maraganore JM, Olson ST, Shafer JA. The COOH-terminal domain of hirudin. J Biol Chem 1990; 265: 13484-9.
• 18 Bouton M-C, Thurieau C, Guillin M-C, Jandot-Perrus M. Characteristics of the interaction between thrombin exosite 1 and the sequence 269-297 of platelet glycoprotein Ibα. Thromb Haemost 1998; 80: 310-5.
• 19 De Cristofaro R, De Candia E, Rutella S, Weitz JI. The Asp²⁷²-Glu²⁸² region of platelet glycoprotein Ib interacts with the heparin-binding site of α-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III. J Biol Chem 2-11-2000 275: 3887-95.
• 20 Marchese P, Murata M, Mazzucato M, Pradella P, De Marco L, Ware J, Ruggeri ZM. Identification of three tyrosine residues of glycoprotein Ib with distinct roles in von Willebrand factor and α-thrombin binding. J Biol Chem 1995; 270: 9571-8.
• 21 Muramatsu R, Komatsu Y, Nukui E, Okayama T, Morikawa T, Kobashi K, Hayashi H. Structure-activity studies on C-terminal hirudin peptides containing sulfated tyrosine residues. International Journal of Peptide and Protein Research 1996; 48: 167-73.
• 22 Mosesson MW, Sherry S. The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry 1966; 5: 2829-35.
• 23 Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to Fibrinogen Molecules Containing γ’ Chains. Biochemistry 1996; 35: 10448-53.
• 24 Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Annals of the New York Academy of Sciences 1983; 408: 28-43.
• 25 Martin BE, Wasiewski WW, Fenton JW II, Detwiler TC. Equillibrium binding of thrombin to platelets. Biochemistry 1976; 15: 4886-93.
• 26 Scopes RK. In: Protein Purification 1. Scopes RK. ed. New York: Springer-Verlag; 1982: 241-3.
• 27 Nakahara T, Waki M, Uchimura H, Hirano M, Kim JS, Matsumoto T, Nakamura K, Ishibashi K, Hirano H, Shiraishi A. Preparation of tyrosineO-[35S] sulfated cholecystokinin octapeptide from a nonsulfated precursor peptide. Anal Biochem 1986; 154: 194-9.
• 28 Huttner WB, Baeuerle PA. Protein Sulfation on Tyrosine In: Modern Cell Bioogy Satir, B. ed. New York: Alan R Liss, Inc.; 1988: 97-140.
• 29 Bundgaard JR, Vuust J, Rehfeld JF. New consensus features for tyrosine O-sulfation determined by mutational analysis. J Biol Chem 1997; 272: 21700-5.
• 30 Moaddel M, Farrell DH. Tyrosine sulfation and γA/γ’ fibrinogen/factor XIII interaction. Blood 1997; 90 (Suppl. 01) 465a.
• 31 Farrell DH, Mulvihill ER, Huang S, Chung DW, Davie EW. Recombinant human fibrinogen and sulfation of the γ’ chain. Biochemistry 1991; 30: 9414-20.
• 32 Henschen AA. On the occurrence and significance of tyrosine sulphate in fibrinogen. Blood Coag Fibrinol 1993; 4: 822.
• 33 Hortin GL. Sulfation of a γ-chain variant of human fibrinogen. Biochem Int 1989; 19: 1355-62.
• 34 Hirose S, Oda K, Ikehara Y. Tyrosine O-sulfation of the fibrinogen γB chain in primary cultures of rat hepatocytes. J Biol Chem 1988; 263: 7426-30.
• 35 Seegers WH, Nieft M, Loomis EC. Note on the adsorption of thrombin on fibrin. Science 1945; 101: 520-1.
• 36 de Bosch NB, Mosesson MW, Ruiz-Saez A, Echenagucia M, Rodriguez-Lemoin A. Effects of γ’/γA chain fibrin on the plasma thrombin generation in afibrinogenemia. Thromb Haemost 1999; 82: 320.
• 37 Francis WC, Markham ER, Barlow HG, Florack MT, Dobrzynski MD, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30.
• 38 Mirshahi M, Soria J, Soria C, Faivre F, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 1989; 74: 1026-30.
• 39 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-23.
• 40 Naski MC, Shafer JA. A kinetic model for the a-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of anti-thrombin III. J Biol Chem 1991; 266: 13003-10.